|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 6 (March 15), 2000:
pp. 2044-2051
IMMUNOBIOLOGY
Engagement of the 2 1 integrin inhibits Fas ligand expression
and activation-induced cell death in T cells in a focal adhesion
kinase-dependent manner
Fawzi Aoudjit and
Kristiina Vuori
From the Cancer Research Center, The Burnham Institute, La Jolla,
CA.
 |
Abstract |
T-cell receptor (TCR)-mediated apoptosis, also known as
activation-induced cell death (AICD), plays an important role in the control of immune response and in the development of T-cell repertoire. Mechanistically, AICD has been largely attributed to the interaction of
Fas ligand (Fas-L) with its cell surface receptor Fas in activated T
cells. Signal transduction mediated by the integrin family of cell
adhesion receptors has been previously shown to modulate apoptosis in a
number of different cell types; in T cells, integrin signaling is known
to be important in cellular response to antigenic challenge by
providing a co-stimulatory signal for TCR. In this study we demonstrate
that signaling via the collagen receptor 2 1 integrin specifically
inhibits AICD by inhibiting Fas-L expression in activated Jurkat T
cells. Engagement of the 2 1 integrin with monoclonal antibodies
or with type I collagen, a cognate ligand for 2 1, reduced
anti-CD3 and PMA/ionomycin-induced cell death by 30% and 40%,
respectively, and the expression of Fas-L mRNA by 50%. Further studies
indicated that the 2 1-mediated inhibition of AICD and Fas-L
expression required the focal adhesion kinase FAK, a known component in
the integrin signaling pathways. These results suggest a role for the
2 1 integrin in the control of homeostasis of immune response and
T-cell development.
(Blood. 2000;95:2044-2051)
© 2000 by The American Society of Hematology.
 |
Introduction |
Programmed cell death, or apoptosis, plays an important
role in the regulation of cellular homeostasis and provides protection against inflammation and cancer. In T lymphocytes, T-cell receptor (TCR)-mediated apoptosis has been shown to be critical for the negative selection of immature T cells within the thymus and in maintaining the peripheral tolerance of mature T cells.1
This so-called activation-induced cell death (AICD) has been largely attributed to the interaction of Fas ligand (Fas-L) with its receptor Fas (CD95),2 and it has been shown to occur in both T-cell clones and T-cell lines, as well as in T-cell
hybridomas.3,4 Stimulation via TCR results in
transcriptional activation of the genes for Fas-L and Fas.2
Subsequent ligation of Fas receptor with Fas-L on the cell surface
induces receptor aggregation, which in turn results in the recruitment
of the adaptor protein FADD and FLICE (caspase-8) and in the activation
of downstream caspases that lead to irreversible cell
damage.5-7 As exemplified by the mutant lpr and
gld mice, loss of function of the Fas/Fas-L pathway leads to
abnormal lymphoproliferation and generalized lymphoproliferative disease.2
Integrins are - heterodimeric membrane proteins that mediate cell
adhesion to the surrounding extracellular matrix (ECM). In addition to
their mechanistic role in anchoring cells to the substratum, integrins
have the capacity to elicit a wide variety of intracellular signals
that regulate cell behavior.8 It is known that several cell
types, such as epithelial and endothelial cells, undergo apoptosis on
loss of integrin-mediated cell attachment, a process referred to as
anoikis.9 Among the signaling molecules involved in
integrin-mediated cell survival is the focal adhesion kinase FAK, which
becomes activated after integrin ligation and may in turn activate
downstream survival pathways such as those composed of
phosphatidylinositol 3'-kinase (PI 3-kinase) and the serine/threonine kinase Akt.9
Lymphocytes express several members of the 1 subfamily of integrins,
which mediate cell attachment, spreading and migration on
ECM.10 The role of 1 integrins in T-cell costimulation
and activation is well documented; several studies have shown that engagement of 1 integrins on activated T cells leads to increased cell proliferation11,12 and tyrosine phosphorylation of
intracellular proteins such as FAK.13,14 Recent evidence
suggests that signals via integrins may modulate T-cell apoptosis,
either by providing a survival signal or by enhancing or inducing a
death signal. For example, the 5 1 integrin has been shown to
mediate protective effects provided by TGF 1 in CD8-positive T cells
against AICD,15 whereas coligation of the 4 1 integrin
and TCR rescues human thymocytes from steroid-induced
apoptosis.16 In antigen-specific T-cell clones, AICD is
enhanced by the coligation of TCR and the 4 1 and L 2 (LFA-1)
integrins.17 Further, fibronectin has been shown to induce
apoptosis in several hematopoietic cell lines, including T
lymphocytes.18 Despite these findings, the exact role of
integrin signaling in AICD and the mechanisms underlying these effects
are unknown.
In this study, we have evaluated the involvement of integrins in the
modulation of TCR-induced apoptosis in Jurkat T cells, which is a
widely used model system in the studies for AICD. We found that
interaction of collagen type I with its receptor 2 1 integrin and
ligation of 2 1 with agonists such as activating antibodies
inhibited CD3- and PMA/ionomycin-induced apoptosis in T cells.
2 1-mediated inhibition of AICD was accompanied by a reduction in
the Fas-L mRNA expression. Ligand binding of 2 1 did not affect
Fas-mediated or cycloheximide-induced apoptosis, suggesting that
2 1 signaling specifically inhibits apoptosis induced on TCR
stimulation. Overexpression of FRNK, a dominant-negative acting form of
FAK, abrogated the effects of 2 1 integrin on both Fas-L
expression and AICD, demonstrating that FAK is required for
2 1-mediated inhibition of AICD. Thus, engagement of the collagen
receptor 2 1 integrin on T cells may be involved in the
regulation of the homeostasis of immune response.
 |
Materials and methods |
Cells, antibodies, and other reagents
Human Jurkat T-cell line was obtained from ATCC and maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mmol/L glutamine and 100 U/mL of penicillin and streptomycin (= complete medium). Cells were passaged 3 times a week to prevent spontaneous apoptosis. Anti-CD3 monoclonal antibody (mAb) Hit3a and
isotype-matched control antibodies were from Pharmingen (San Diego,
CA). Mouse antihuman Fas antibodies (CH-11 and UB2) were from Kamiya
Biomedicals (Seattle, WA) and anti-Fas-L antibody was from Transduction
Laboratories (Lexington, KY). Blocking anti- 1 (FB12) and anti- 2
(PIE6) integrin antibodies, as well as activating anti- 1 (B44) and
anti- 2 1 (JSB2) mAbs, were from Chemicon (Temecula, CA). PMA was
from Sigma and ionomycin was from Calbiochem (San Diego, CA). Purified
bovine type I collagen and mouse laminin were from Becton Dickinson
(Bedford, MA) and Gibco-BRL (Grand Island, NY), respectively. Human
fibronectin was obtained from Finnish Red Cross and poly-l-lysine from Sigma.
Activation-induced cell death and determination of apoptosis
Cells were suspended at 0.5 × 106 cells/mL in
complete medium, plated on wells of 96-well plates in triplicate
samples (0.5 × 105 cells per well), and incubated
with or without stimuli for 24 hours. For TCR stimulation, wells had
been precoated with 50 µg/mL of anti-CD3 antibody in
phosphate-buffered saline (PBS) overnight. PMA and ionomycin
stimulations were carried out at concentrations of 50 ng/mL and 0.5 µg/mL, respectively. Activating anti-integrin antibodies and their
isotype-matched controls were immobilized on plates at a concentration
of 50 µg/mL. ECM proteins fibronectin, laminin and collagen I and the
nonintegrin ligand poly-l-lysine were used in the soluble form at
concentrations ranging from 25 to 100 µg/mL. Inhibitory anti-integrin
antibodies were used at a concentration of 25 µg/mL. The percentage
of cell death was calculated by using trypan blue dye exclusion (total
number of blue cells/total number of cells × 100). Apoptotic cell
death was monitored by measuring DNA fragmentation using the Cell Death Detection ELISA kit according to manufacturer's instructions
(Boehringer Mannheim, Indianapolis, IN). In some of the experiments,
apoptosis was also determined by propidium iodide and FACScan®
analysis (Becton Dickinson). Briefly, stimulated cells were washed
twice with ice-cold PBS and 5 µg/mL propidium iodide was added to the cells followed by immediate FACScan® analysis. Apoptotic cells were
identified as those taking up the dye.
Plasmids and transient transfections
Plasmids encoding the wild-type form of FAK and its
dominant-negative acting form known as FRNK (FAK-related nonkinase)
have been described in Whitney et al19 and Zhao et
al,20 respectively. The 1.2 kb human Fas-L promoter in
front of the Luciferase reporter gene becomes transactivated after TCR
activation and has been described previously.21 Cells were
transfected by electroporation using a BTX electroporator 600 (BTX, San
Diego, CA) according to the manufacturer's protocol. Briefly, 20 million cells in log-phase growth were harvested, washed twice with
PBS, and resuspended in 0.4 mL of complete medium containing 50 µg of
total plasmid DNA. Electroporation was carried out at the settings of
1600 µF, 150 V, and 72 ohms. Cotransfection with the pCMV
-galactosidase plasmid was used to normalize the transfection
efficiency. Forty-eight hours after transfection, viable cells were
recovered by Ficoll-Hypaque (Sigma) density gradient centrifugation.
The cells were then washed 3 times in PBS and used for subsequent cell
death experiments.
Luciferase assays
After transfection as above, cells were harvested and stimulated
with either anti-CD3 or with PMA/ionomycin for 24 hours. Luciferase
activity was measured by using the Luciferase Assay System (Promega)
according to the manufacturer's protocol and a monolight 2010 luminometer.
Cell adhesion assays
A 96-well microtiter plate (TC plate, flat bottom, Falcon) was
coated with 20 µg/mL of collagen I, fibronectin or poly-l-lysine in
PBS, pH 7.4 for 2 hours at 37°C. The wells were then washed with
PBS and blocked for 1 hour at 37°C with 1% bovine serum albumin (BSA) (Sigma). Five × 104 cells in 0.1 mL of
complete medium were added to the wells. The cells were then incubated
for 1 hour at 37°C in the presence or absence of anti-CD-3 or
PMA/ionomycin. In some of the experiments, 25 µg/mL of blocking
anti- 1 and - 2 integrin antibodies were added to the cells 30 minutes before cellular activation. After incubation, the cells were
washed gently 3 times in PBS and fixed with 1% glutaraldehyde, 0.5%
sucrose in PBS for 15 minutes at room temperature. After 2 washes with
PBS, the cells were stained with 0.5% Crystal violet in 20%
methanol/PBS for 30 minutes at room temperature. The cells were then
washed 5 times with PBS and the cell-bound stain was resolubilized in
methanol and absorbance was measured at 600 nm.
Flow cytometric analysis
1 × 106 cells in 0.1 mL of PBS containing 1% FCS and
0.2% sodium azide (FACS buffer) were incubated with 10 µg/mL of
anti-Fas mAb UB2 or isotype-matched control antibodies for 30 minutes
at 4°C. The cells were washed 3 times in PBS and incubated with
phycoerethryn-conjugated goat antimouse IgG secondary antibodies at a
dilution of 1:100 (Jackson ImmunoResearch Laboratories, West Grove, PA)
in 0.1 mL of FACS buffer for another 30 minutes. The cells were washed
3 times in PBS and analyzed with a FACScan® (Becton Dickinson).
Cytotoxicity assay
Lysis of the Hut-78 lymphoma cell line, which is sensitive to
Fas-mediated cell death, was used as an indicator of Fas-L surface expression. Hut-78 cells were grown in complete RPMI 1640 medium and
were labeled with 51Cr as previously
described.22 The labeled cells were used as a target for
Jurkat cells that had been previously stimulated with 50 µg/mL of
anti-CD3 for 8 hours to allow for Fas-L expression. Stimulation was
carried out in the presence or absence of 50 µg/mL of poly-l-lysine
or collagen I. Various concentrations of Jurkat cells were cocultured
with 51Cr-labeled Hut-78 for 12 hours, and the release of
51Cr was determined with a gamma counter. Spontaneous
release of 51Cr was also determined. The percentage of
specific cell lysis was calculated as previously
described.22
Immunoprecipitation and immunoblotting
Jurkat cells (5 × 106/0.5 mL serum-free medium)
were washed twice with RPMI without serum and stimulated or not with
anti-CD3, collagen I, or combination of the two for 10 minutes. Cell
lysate preparations, immunoprecipitations with anti-FAK antibody
(Transduction Laboratories), as well as immunoblotting with
HRPO-conjugated anti-phosphotyrosine py20 antibody (Transduction
Laboratories) and with the anti-FAK antibody, followed by enhanced
chemiluminescence detection (Pierce, Rockford, IL) were carried out as
by Vuori and Ruoslahti.23
 |
Results |
Engagement of 1 integrins decreases activation-induced cell death
in Jurkat cells
The 1 integrin-positive human leukemic Jurkat T cell line is a
widely used cellular model for activation-induced cell death, or AICD,
as activation of these cells via TCR leads to up-regulation of Fas-L
mRNA and subsequently to AICD and apoptosis.3 Stimulation of T cells with PMA and ionomycin mimics the effects of TCR ligation, and similarly induces apoptosis in a Fas-dependent
manner.24 To examine the role of 1 integrin signaling in
activation-induced cell death in human T lymphocytes, we used the
Jurkat cell model and studied the effect of 1 integrin engagement on
CD3-and PMA/ionomycin-induced apoptosis. As shown in Figure
1, Jurkat T cells undergo apoptosis on
activation of TCR by anti-CD3 antibodies. Addition of activating anti- 1 integrin antibodies, together with anti-CD3 antibody, reduced
anti-CD3-induced apoptosis, as evidenced by the 25% inhibition of DNA
fragmentation. In contrast, isotype-matched control antibodies had no
effect on anti-CD3-induced apoptosis. Similar inhibitory effects by
anti- 1 integrin antibodies were observed on PMA/ionomycin-induced apoptosis (data not shown).

View larger version (22K):
[in this window]
[in a new window]
| Fig 1.
1 integrin signaling inhibits AICD in Jurkat cells.
Jurkat cells were stimulated with or without 50 µg/mL of immobilized
anti-CD3 antibody for 24 hours in the presence or absence of 50 µg/mL
of immobilized anti- 1 or IgG control antibodies. Apoptosis was
determined by DNA fragmentation analysis as described in "Materials
and methods." The results are mean of 3 independent experiments,
each done in a duplicate. *P < .05 between
anti-CD3-stimulated control and anti- 1 antibody samples.
|
|
The 1 integrin subunit is shared by several ECM receptors on Jurkat
T cells, and we next determined which ECM protein(s) can mimic the
effects of the activating anti- 1 integrin antibodies on AICD. Jurkat
cells were stimulated with apoptotic anti-CD3 or PMA/ionomycin stimuli
in the presence of 75 µg/mL of various purified ECM proteins, such as
fibronectin, laminin, and collagen I, and cell death was determined 24 hours later. The nonintegrin ligand poly-l-lysine was used as a
control. Cell treatment with collagen I, but not with fibronectin,
laminin or poly-l-lysine, protected Jurkat T cells from AICD; DNA
fragmentation was inhibited by 32% (Figure
2A) and the number of viable cells was
increased by 38% in collagen I-treated cells (Figure 2B). Further
studies indicated that the effects of collagen I on AICD were
dose-dependent (Figure 2C). Preincubation of Jurkat cells for 1, 3, or
6 hours with collagen I before the exposure of the cells to anti-CD3
did not increase cell survival compared with when cells had been
treated with collagen I and anti-CD3 at the same time (data not shown). Together, these results indicate that 1 integrin signaling
through the collagen I integrin receptors provides a survival signal in T lymphocytes by inhibiting AICD and apoptosis.

View larger version (18K):
[in this window]
[in a new window]
| Fig 2.
Collagen type I inhibits AICD in Jurkat cells.
(A) Jurkat cells were stimulated with or without immobilized anti-CD3
antibody for 24 hours in the presence or absence of 50 µg/mL of the
indicated ECM proteins. Apoptosis was determined by DNA fragmentation
analysis. Fn, fibronectin; Ln, laminin; Coll, collagen I. *P < .05 between anti-CD3-stimulated control and
collagen-treated samples. (B) Cells were stimulated with or without
PMA/ionomycin for 24 hours in the presence or absence of 50 µg/mL of
collagen I (Coll I) or poly-l-lysine (PLL). Cell death was determined
by propidium iodide uptake as described in "Materials and
methods." *P < .05 between PMA/ionomycin-stimulated
control and collagen-treated samples. (C) Dose-response effect of
collagen I on AICD. The results are representative of 3 independent
experiments.
|
|
A specific role for the 2 1 integrin in activation-induced
cell death
Collagen I can bind to several members of the 1 integrin family,
at least 2 of which, the 1 1 or 2 1 integrins, are known to
be expressed in Jurkat cells. Previous studies have demonstrated that
the 2 1 integrin is likely to be the functional receptor for
collagen I in these cells.25,26 To confirm and extend these findings, Jurkat cells were stimulated with PMA/ionomycin in the presence of soluble collagen I (75 µg/mL) and blocking antibodies directed against 1 1 or 2 1 integrins; isotype-matched
antibodies were used as a control. As shown in Figure
3A, the protective effects of collagen I on
AICD were completely abrogated by anti- 2 1 blocking antibodies,
whereas blocking anti- 1 1 antibodies and the isotype-matched
control antibodies had no effect on collagen I-mediated protection from
apoptosis. These results indicate that the effects of collagen I on
AICD are likely to be mediated through its interaction with the
2 1 integrin receptor. These results were supported by the finding
that the blocking anti- 2 1 antibody inhibits the adhesion of
PMA/ionomycin-activated Jurkat cells to collagen I-coated wells by
85%, whereas the blocking anti- 1 1 antibody did not have any
effect (Figure 3B). In conclusion, our results demonstrate that
activation of Jurkat cells induces cell adhesion to collagen I via the
2 1 integrin and that the collagen I- 2 1 integrin interaction
inhibits AICD.

View larger version (18K):
[in this window]
[in a new window]
| Fig 3.
Collagen I-induced inhibition of AICD in Jurkat cells is
mediated by the 2 1 integrin.
(A) Jurkat cells were stimulated with or without anti-CD3 and collagen
I in the presence or absence of inhibitory antibodies against 1 and
2 integrin subunits or control antibodies (IgG). The anti-integrin
antibodies were used at 25 µg/mL and were added 30 minutes before
plating the cells on anti-CD3-coated wells. The cells were then
cultured for 24 hours and cell death was determined by DNA
fragmentation assay. (B) Adhesion assay of Jurkat cells on immobilized
collagen I. Cells were activated or not with PMA/ionomycin
and plated on wells that had been coated with collagen I and were
allowed to attach for 1 hour at 37°C. 25 µg/mL of inhibitory
anti- 1 and anti- 2 integrin antibodies were added to the wells as
indicated in the figure. Adhesion was quantified as described in
"Materials and methods." The results are representative of 3 different experiments performed in triplicates.
|
|
To gain more insight into the protective function of 2 1, we
studied whether direct activation of this integrin by the activating anti- 2 1 mAb JSB2, which is known to transduce intracellular signals in Jurkat cells,27 could also block AICD. Indeed,
CD3-induced cell death was inhibited by 40% in the presence of the
anti- 2 1 mAb JSB2, whereas its isotype-matched control antibody
did not have any effect (Figure 4). Thus,
signals via the 2 1 integrin can rescue T lymphocytes from AICD.
We next investigated whether 2 1 signaling can inhibit other forms
of apoptosis in Jurkat cells and analyzed the effects of the JSB2
antibody and collagen I on cycloheximide-induced apoptosis. Treatment
of Jurkat cells with cycloheximide (20 µg/mL) for 6 hours induced
significant cell death that was not abrogated by either collagen I or
JSB2 (Figure 5A); similar results were
obtained with cycloheximide concentrations ranging from 5 to 20 µg/mL
(data not shown). These findings demonstrate that signaling via the
2 1 integrin is unable to inhibit apoptosis induced by
cycloheximide, and suggest that the ability of 2 1 to inhibit AICD
in Jurkat cells is specific so that engagement of this integrin does
not result in a general inhibitory effect on cell death.

View larger version (14K):
[in this window]
[in a new window]
| Fig 4.
Effect of 2 1 antibody cross-linking on AICD.
Jurkat cells were cultured for 24 hours in wells that had been coated
with anti-CD3 and with 50 µg/mL of activating anti- 2 1 antibody
JSB2 or with control antibodies (IgG). 50 µg/mL of poly-l-lysine or
collagen I was added to some of the wells as indicated in the figure.
DNA fragmentation was determined as previously described.
|
|


View larger version (1715K):
[in this window]
[in a new window]
| Fig 5.
Engagement of the 2 1 integrin does not inhibit
cycloheximide- or Fas-induced apoptosis in Jurkat cells.
Jurkat cells were stimulated with 20 µg/mL of cycloheximide for 6 hours (A) or with 1 µg/mL of anti-Fas antibody CH-11 for 24 hours (B)
in the presence or absence of 50 µg/mL of collagen I or
poly-l-lysine, or 50 µg/mL of immobilized activating anti- 2 1
antibody JSB2 or control antibodies. Apoptosis was determined by DNA
fragmentation as previously described.
|
|
Collagen prevents activation-induced cell death by inhibiting Fas
ligand mRNA expression
It has been previously demonstrated that AICD proceeds via induction
of Fas-L mRNA expression and subsequent Fas/Fas-L interaction on the
surface of activated T cells.2,3 Therefore, the observed inhibition of AICD by collagen I could conceivably be mediated by at
least 3 nonexclusive mechanisms: by inhibition of Fas-L expression, by
inhibition of Fas receptor expression, or by inhibition of apoptotic
signaling events downstream of Fas ligation. To study the latter
possibility, we analyzed whether Fas-mediated cell death can be blocked
by 2 1 signaling. When anti-Fas was used at 1 µg/mL, neither
collagen I (100 µg/mL) nor activating anti- 2 1 mAb JSB2 blocked
anti-Fas-induced cell death (Figure 5B), suggesting that 2 1
integrin does not interfere with apoptotic signals propagated by Fas
ligation. We next established that the 2 1 signaling does not
affect the levels of Fas receptor on the cell surface; FACS® analysis demonstrated that after 8 hours of PMA/ionomycin treatment, the constitutive levels of Fas receptor on the cell surface remained unchanged in the presence and absence of 2 1 ligation (Figure 6). Similar results were obtained after 24 hours of stimulation with anti-CD3 or with PMA/ionomycin (data not
shown). Finally, we determined the effect of 2 1 ligation on Fas-L
expression in activated T cells. The transcription of the Fas-L gene
was evaluated by using Fas-L promoter construct in a reporter gene transactivation assay. Also, the expression of Fas-L on the surface of
CD3-activated Jurkat cells was assessed by functional analysis using
51Cr-labeled Hut-78 as a target population. We found that
collagen I inhibits the transactivation of Fas-L promoter induced by
anti-CD3 and by PMA/ionomycin, as evidenced by a 50% inhibition of
Fas-L promoter-driven luciferase activity by collagen I (50 µg/mL), but not by poly-l-lysine (50 µg/mL) in activated Jurkat cells (Figure
7A). Further, 2 1 signaling was found
to inhibit the expression of Fas-L on the surface of activated Jurkat
cells, most likely because of the inhibition of Fas-L mRNA expression. As shown in Figure 7B, stimulation of Jurkat cells with anti-CD3 resulted in Fas-L expression on the cell surface as evidenced by the
ability of stimulated Jurkat cells to induce apoptosis in Fas-sensitive
Hut78 cells. In the presence of collagen I, but not of
poly-l-lysine, the ability of anti-CD3-stimulated Jurkat cells to
induce cytotoxicity in Hut-78 cells was inhibited by 35%, suggesting
that Fas-L expression is inhibited by 2 1 signaling in activated
Jurkat cells (Figure 7B). Similar results were obtained when the
protein expression levels of Fas-L were analyzed by immunoblot analysis; treatment of PMA/ionomycin-stimulated Jurkat cells with 50 mg/mL of collagen I inhibited Fas-L protein expression levels by 40%
(data not shown). In conclusion, collagen I appears to prevent
CD3-mediated AICD by inhibiting the induction of Fas-L expression in
T cells.

View larger version (20K):
[in this window]
[in a new window]
| Fig 6.
FACS analysis of Fas antigen expression on the surface of
Jurkat cells.
Jurkat cells were treated for 8 hours with PMA/ionomycin in the
presence or absence of 100 µg/mL of poly-l-lysine or collagen I. The
cells were harvested and stained as described in "Methods." The
upper left panel represents negative and positive staining of
unstimulated Jurkat cells with an isotype-matched control antibody and
anti-Fas antibody, respectively. The 3 other panels show antiFas
staining in stimulated Jurkat cells that had been treated with
PMA/ ionomycin, poly-l-lysine and collagen I as indicated. X axis,
relative fluorescence intensity; Y axis, cell number.
|
|


View larger version (1416K):
[in this window]
[in a new window]
| Fig 7.
Collagen I inhibits AICD by modulating Fas-L expression.
(A) Collagen I inhibits transcriptional activity of the Fas-L promoter
in activated Jurkat cells. Jurkat cells were transiently transfected
with luciferase reporter construct containing the 1.2 kb Fas-L promoter
together with a pCMV -Gal plasmid encoding -galactosidase. 48 hours after transfection, the cells were stimulated with or without
PMA/ionomycin in the presence or absence of 50 µg/mL of poly-l-lysine
and collagen I. The relative luciferase activity (RLU) was determined
18 hours after stimulation. *P < .05 between
PMA/ionomycin-stimulated control and collagen-treated samples. (B)
Collagen inhibits Fas-L expression on the cell surface as determined by
a cytotoxicity assay. Jurkat cells were stimulated with 50 µg/mL of
anti-CD3 for 6 hours to allow for Fas-L expression. As indicated, 50 µg/mL of collagen I or poly-l-lysine was added. The cells were
harvested, washed twice with PBS, and incubated with
51Cr-labeled Hut-78 cells for 12 hours. The percentage of
cytotoxicity was determined as described in "Materials and
methods." The results are mean of 2 experiments performed in
triplicates. *P < .05 between anti-CD3-stimulated control
and collagen-treated samples.
|
|
Focal adhesion kinase FAK is required for the inhibition of
activation-induced cell death and Fas ligand expression by collagen I
Previous studies have demonstrated that activation and tyrosine
phosphorylation of FAK is crucial for cell survival signals downstream
of integrins in multiple cellular systems.9 Also, it has
been demonstrated that stimulation via CD3 and integrins results in a
rapid (within 5 minutes) tyrosine phosphorylation of FAK and the
phosphorylation levels are maintained high up to 2 hours in Jurkat
cells.28,29 To determine whether FAK is involved in
2 1-mediated inhibition of AICD, we first studied whether FAK
becomes tyrosine-phosphorylated in response to 2 1 ligation in
Jurkat cells. As shown in Figure 8A, low,
20 µg/mL concentration of collagen I had no significant effect on the
basal tyrosine phosphorylation level of FAK. Densitometry analysis
demonstrated a 2-fold increase in FAK phosphorylation on stimulation of
cells with higher, 50 µg/mL concentration of collagen I. A similar
2-fold induction in FAK phosphorylation was observed when cells were stimulated with 20 µg/mL anti-CD3 antibody. Simultaneous stimulation of cells with 20 µg/mL of anti-CD3 and 50 µg/mL of collagen I resulted in a 3-fold induction in FAK phosphorylation (Figure 8A).
These results demonstrate that 2 1 ligation either alone or in
combination with anti-CD3 increases FAK tyrosine phosphorylation in
Jurkat cells.

View larger version (28K):
[in this window]
[in a new window]
| Fig 8.
FAK is phosphorylated in response to 2 1 ligation
and mediates 2 1-induced inhibition of AICD and Fas-L expression.
(A) The cells were stimulated or not with collagen I at 20 and 50 µg/mL either alone or in combination with 20 µg/mL of soluble
anti-CD3 for 10 minutes. The cells were washed and lysed and subjected
to immunoprecipitation with anti-FAK antibodies. The immunoprecipitates
were analyzed by immunoblotting with anti-phosphotyrosine antibodies
(top panel) and with antibodies against FAK (lower panel). (B) Jurkat
cells were cotransfected with a plasmid encoding the dominant-negative
form of FAK (FRNK), wild-type form of FAK (FAK), combination of FRNK-
and FAK-encoding plasmids, or a control plasmid, together with a
plasmid encoding GFP as described in "Materials and methods."
Viable cells were recovered 48 hours later by Ficoll gradient and
stimulated with or without PMA and ionomycin in the presence or absence
of 50 µg/mL collagen I for 24 hours. The cells were then washed and
propidium iodide was added for 15 minutes on ice, and apoptosis was
analyzed by FACScan®. The analysis was carried out on the double
positive cell population for propidium iodide and fluorescent GFP. (C)
Jurkat cells were cotransfected with plasmids encoding FRNK, FAK, Fas-L
promoter reporter construct, and -galactosidase. After 48 hours, the
cells were washed and treated with the various stimuli as in (B) and
luciferase activity (RLU) was determined after 18 hours.
|
|
The C-terminal domain of FAK is expressed in some cells as an
alternatively spliced form known as FRNK (FAK-related nonkinase), which
is devoid of any tyrosine kinase activity.30 Exogenous expression of FRNK has been shown to interfere with the endogenous FAK
signaling in a dominant-negative fashion,31,32 and
therefore provides an efficient tool to dissect the signaling pathways
downstream of FAK. Accordingly, we investigated next the role of FAK in
collagen I-induced inhibition of AICD by exogenous expression of FRNK
in Jurkat cells. The cells were transiently transfected with plasmids encoding FRNK or control plasmids, together with a plasmid encoding the
green fluorescent protein (GFP) to allow detection of transfected cells. The ability of collagen I to protect the cells from AICD was
then assessed. As shown in Figure 8B, expression of FRNK per se had no
effect on the viability of Jurkat cells. The protective effects of
collagen I on AICD, however, were abrogated by 85% in cells that had
been transfected with FRNK, but not in cells that had been transfected
with control plasmids. Hence, these results suggest that FAK has an
important role in mediating the protective effects of 2 1 on AICD.
In support of this, we found that exogenous expression of wild-type FAK
increased the capacity of collagen I to protect the cells from AICD
without affecting the overall viability of Jurkat cells (Figure 8B). In
addition, coexpression of wild-type FAK with FRNK completely rescued
the effect of FRNK on collagen-mediated cell survival, confirming that
exogenously expressed FRNK specifically interferes with FAK signaling
in Jurkat cells (Figure 8B).
We also examined whether exogenous expression of FRNK influences
collagen I-induced inhibition of Fas-L promoter activity in activated
Jurkat cells. Cells were transfected with a Fas-L reporter gene plasmid
together with an FRNK encoding or control plasmid. As shown in Figure
8C, exogenous expression of FRNK abrogated the inhibitory effects of
collagen I on PMA/ionomycin-induced Fas-L promoter activity by 80%,
without affecting the basal Fas-L promoter activity. Exogenous
expression of wild-type FAK in turn enhanced the ability of collagen to
inhibit Fas-L promoter activity, and coexpression of wild-type FAK with
FRNK abolished the inhibitory effect of FRNK on 2 1 signaling.
Exogenous expression of FAK did not have any effect on the basal Fas-L
promoter activity (Figure 8C). Together, these results indicate that
FAK is required for the inhibition of both Fas-L promoter activity and
AICD in activated Jurkat cells by 2 1 signaling.
 |
Discussion |
Integrin signaling has been shown to protect various cell types from
apoptosis and to play an important role in providing costimulatory
signals in T cells. In agreement with a previous report,33
we demonstrate here that treatment of Jurkat T cells with an activating
anti- 1 antibody inhibits AICD, suggesting that signaling via 1
integrin(s) interferes with signals for AICD in T lymphocytes. We have
extended these studies and identified 2 1 as the 1 integrin
that is responsible for these effects, at least in Jurkat T cells. An
2 1 integrin ligand collagen I and activating antibodies against
2 1 inhibited AICD, but had no effect on cycloheximide-induced
cell death. We further show that activation of Jurkat cells induces
cell binding to collagen I via 2 1 integrin, which subsequently
results in the inhibition of AICD. Together, these results indicate
that 2 1 may have an important role the regulation of AICD and in
the maintenance of the homeostasis of the immune system.
Our results demonstrate that only 2 1, but not the other 1
integrins that act as receptors for, eg, laminin and fibronectin, signal for inhibition of AICD in Jurkat cells. As a matter of fact,
fibronectin, which interacts mainly with the 4 1 integrin in
Jurkat cells (data not shown and Mobley et al34) slightly enhanced AICD at later time points (48 hours) (data not shown). These
results are in agreement with a previous report demonstrating that in
antigen-specific T-cell clones, stimulation of 4 1 with its ligand
VCAM-1 synergizes with TCR signals in inducing apoptosis.17 Interestingly, it has been demonstrated that the protective effects of
TGF 1 on cell survival in CD8+ T cells are mediated through another
fibronectin receptor, the 5 1 integrin.15 These
observations suggest that T cells may respond differentially to their
tissue microenvironment, depending on the expression profile and
activation state of the integrin receptors on the cell surface.
Similarly, the cells appear to use different ECM receptors to perform
different biologic functions. The exact mechanisms by which integrins
link to specific intracellular signaling pathways to create the
appropriate cellular responses are unknown at present.
Although the in vivo importance of our findings remains to be
determined, the results reported here nevertheless add to the notion
that integrins not only modulate T-cell activation and migration but
they also regulate lymphocyte apoptosis. The 2 1 integrin is also
known as VLA-2 for "very late antigen-2," and, unlike some other
VLA-denoted integrins, it is considered as a "true" very late
T-cell activation antigen as it appears 2 to 4 weeks after in vitro
activation of T lymphocytes.35 Our results suggest that a
function for the 2 1 integrin may be to inhibit AICD during the
late stages of T-cell activation. Collagen type I is a very abundant
extracellular matrix protein in connective tissues of skin, tendon, and
bone, and it is the main collagen type produced by dermal
fibroblasts.36 It can be envisioned that T lymphocytes may
encounter collagen I during the immune response in tissues that are
rich in collagen I; this may occur, for example, during the elimination
of infected cells on viral infections. The 2 1 integrin-collagen I
interaction may facilitate the development of memory cells in these
situations. Also, expression levels of collagen type I are upregulated
in certain inflammatory and autoimmune disease conditions, such as
systemic sclerosis.37 Thus, the 2 1 integrin-collagen
I interaction may also play a role in chronic inflammatory diseases:
interaction of activated T cells with collagen I could result in
hyperactivation of T cells due to inhibition of apoptosis, which in
turn may lead to an uncontrolled inflammatory response and tissue
damage. Along these lines, CD44, which is another cell adhesion
molecule and which also protects T cells from AICD,38 has
been linked to the development of T-cell memory. It has been shown that
only CD44 positive cells survive and develop into T memory cells during
peripheral T lymphocyte depletion.39 Inhibition of AICD via
1 integrins may also have a role in promoting activation of
autoreactive lymphocytes in various autoimmune and inflammatory
diseases; in rheumatoid arthritis, the ratio of 1 1 and 2 1
integrins on synovial fluid T lymphocytes is associated with stages of
T-cell activation.40 These observations indicate that
adhesion molecules may be important in controlling lymphocyte
homeostasis and peripheral depletion by modulating apoptotic signals
triggered via TCR and perhaps also via other membrane receptors.
Our results demonstrate that ligation of the 2 1 integrin inhibits
AICD by inhibiting transcriptional activation of the Fas-L gene. In
previous studies, the mechanism(s) by which integrins or other adhesion
molecules modulate survival and apoptosis in T cells has not been
addressed. In contrast to its effects on Fas-L expression, 2 1
ligation had no effect on Fas antigen expression or on Fas
antigen-mediated activation of cell death pathways. We found, however,
that when the stimulatory anti-Fas CH-11 mAb was used at lower doses
(0.1 µg/mL), ligation of 2 1 was able to inhibit Fas-mediated
cell death by 30% (data not shown), suggesting that signaling via
2 1 may interfere with Fas-signaling pathway under some
conditions. Our results are similar to the previous reports that
demonstrate that CD28, CD2, and TGF 1 signaling inhibits AICD by
inhibiting Fas-L expression.22,41,42 Together, these results suggest that modulation of Fas-L expression may be a critical checkpoint in AICD. Stimulation of T cells via TCR on the cell surface
transduces a series of intracellular signals that eventually lead to
Fas-L expression and AICD.43 One explanation for the observed inhibitory effects of 2 1 ligation on Fas-L expression could be the sequestration of the TCR signaling complex at the cell
surface. This is unlikely to be the case, however, as we found that
2 1 ligation also inhibits PMA/ionomycin-induced AICD by the same
mechanism. Expression of Fas-L downstream of TCR is regulated by
transcription factors such as NF- B, c-myc, NF-AT, and
Egr-3,21,41,42,44-46 and it has been shown that TGF 1
inhibits Fas-L expression and subsequent AICD via down-regulation of
c-Myc.42 We are currently exploring the possibility that
2 1 signaling functions by inhibiting the activity of one of these
transcription factors.
Our studies identify a functional role for the focal adhesion kinase
FAK in T cells, as we find that FAK is a crucial component in the
2 1 signaling pathways that mediate inhibition of Fas-L expression
and AICD. Our results are in agreement with the role of FAK in
protecting against anoikis and serum deprivation-induced cell death in
adherent cells.47,48 Along these lines, it was reported
previously that 1 integrin signaling increases expression of FAK
mRNA, which in part may be responsible for the protective signaling
effects of 1 integrins in T-cells.33 Also, FAK has been
found to become proteolytically cleaved during Fas-mediated apoptosis
in Jurkat cells.49 Together, these findings contribute to
the emerging picture that FAK is a key element in cell survival not
only in adherent cells but also in nonadherent cells such as T
lymphocytes. In agreement with previous publications,28,29 we found that CD3 occupancy also causes FAK phosphorylation. At present, the significance of this finding is unknown. Our results suggest that FAK activation does not partake in modulation of cell
death directly downstream of CD3, as expression of dominant-negative FRNK had no effect on CD3-induced Fas-L expression and apoptosis (Figure 8). One possibility is that FAK would play a role in modulating cytoskeletal responses downstream of CD3. Indeed, recent findings indicate that the docking protein Cas-L, which is one of the FAK targets in T cells, mediates cell migratory events in response to CD3
ligation.50 Because FAK is promoting cell survival
downstream of 2 1 integrin, it seems paradoxical that FAK is also
activated on TCR ligation. However, it is not uncommon that a signaling molecule that promotes cell survival would become activated also downstream of stimuli that lead to apoptosis. For example, activation of PI 3-kinase, which mediates cell survival downstream of a number of
cell surface receptors,51 also becomes activated on TCR
ligation.52 Furthermore, activation of NF- B is known to
promote cell survival, but NF- B nevertheless is also activated on
TNF -induced cell death.53 The mechanisms by which FAK
transduces the protective effects of integrin signaling to the
regulation of Fas-L expression and AICD are unknown. It should be noted
that activation and tyrosine phosphorylation of FAK is not specific for
2 1 integrin ligation in Jurkat cells: stimulation of 4 1
integrin (data not shown, and Maguire et al29) signaling
pathways also leads to FAK phosphorylation. It is therefore possible
that additional specific signals triggered by 2 1 ligation
contribute to the inhibition of AICD. In this regard, it has been shown
that cross-linking of 2 1 with activating antibodies induces
tyrosine phosphorylation of several intracellular proteins and leads to
accumulation of active p21 Ras molecules in Jurkat cells.27
Further elucidation of the mechanisms by which 2 1 signaling
inhibits Fas-L transcription and AICD is likely to provide new
important insights into the role of integrin signaling in the
regulation of T-cell homeostasis in normal and pathologic conditions.
 |
Acknowledgments |
We are grateful to Dr Douglas Green (La Jolla Institute for Allergy and
Immunology, San Diego, CA) and Dr Jun-Lin Guan (Cornell University, NY)
for providing the reporter gene construct of human Fas-L promoter and
the dominant-negative FRNK plasmid, respectively. We also thank Dr Reem
Al-Daccak (Laval University, Quebec, Canada) for helpful discussions.
|